Xeris Biopharma Holdings
XERS
143 hedge funds and large institutions have $134M invested in Xeris Biopharma Holdings in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 47 increasing their positions, 34 reducing their positions, and 13 closing their positions.
177% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 13
144% more call options, than puts
Call options by funds: $826K | Put options by funds: $339K
38% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 34
19% more funds holding
Funds holding: 120 → 143 (+23)
1.11% less ownership
Funds ownership: 44.27% → 43.16% (-1.1%)
7% less capital invested
Capital invested by funds: $144M → $134M (-$9.73M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$3.71M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$3.02M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.25M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.35M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$13.8M |
| 2 |
Morgan Stanley
New York
|
-$2.98M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$1.87M |
| 4 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$1.37M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.05M |
XERS Hedge Fund Activity: Q1 2024 in Review
143 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2024, worth a combined $134M — down 6.8% from $144M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new XERS positions and 13 closed out — a net gain of 23 holders — while 47 added to existing stakes and 34 trimmed.
The largest buyer was CenterBook Partners, adding an estimated $3.71M. The largest seller was Stonepine Capital Management, cutting an estimated $13.8M.
- 143 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2024, up from 120 in Q4 2023.
- Funds reported $134M of Xeris Biopharma Holdings stock for Q1 2024, down 6.8% quarter-over-quarter.
- 36 funds opened new Xeris Biopharma Holdings positions in Q1 2024 and 13 closed out, a net change of +23 holders.
- The largest Xeris Biopharma Holdings buyer in Q1 2024 was CenterBook Partners, an estimated $3.71M added.
- The largest Xeris Biopharma Holdings seller in Q1 2024 was Stonepine Capital Management, an estimated $13.8M sold.
Based on aggregated 13F filings for Q1 2024.